Loyal is developing therapies designed to target biological processes associated with aging in dogs. Instead of focusing on individual age-related diseases, the company’s research aims to address mechanisms linked to age-related decline and lifespan reduction.
Its pipeline focuses on two canine populations: senior dogs, through treatments targeting metabolic changes associated with aging, and large and giant-breed dogs, whose shorter lifespans have been associated with growth and hormonal pathways. Loyal’s patent portfolio reflects these research areas, covering drug formulations, metabolic interventions, endocrine biology, and biomarker-based approaches to studying canine aging.
Loyal’s two distinct approaches to canine longevity
Loyal has structured its development pipeline (LOY-001, LOY-002, and LOY-003) around two canine populations with different longevity challenges.
The lead program, LOY-002, is being developed for senior dogs as a daily oral therapy designed to improve age-associated metabolic dysfunction, which Loyal identifies as a key contributor to declining health and lifespan in older animals. In January 2026, the FDA’s Center for Veterinary Medicine accepted the Target Animal Safety (TAS) section of LOY-002‘s Expanded Conditional Approval (XCA) application, marking a significant regulatory milestone and completing two of the three major components required for conditional approval.
In contrast, LOY-001 and LOY-003 target the biological mechanisms believed to underlie the lifespan disparity between large and small dogs. The two products employ different delivery methods, LOY-001 as a veterinarian-administered long-acting treatment and LOY-003 as a daily pill, but are directed at the same longevity challenge.
Investor support reinforces Loyal’s longevity drug ambitions
Loyal has secured significant funding as it advances what could become the first FDA-approved longevity drug for dogs. The company raised $45 million in a Series B financing in 2024 led by Bain Capital Ventures, bringing total funding at the time to more than $125 million. Wilson Sonsini, which advised Loyal on patent matters related to the transaction, said the capital was intended to support continued product development and advance the company’s regulatory objectives.
Investor support accelerated further in 2026 when Loyal announced a $100 million Series C financing led by age1, with participation from Baillie Gifford and existing investors. The company said the proceeds would be used to advance LOY-002, its lead longevity drug candidate for senior dogs, through the final stages of FDA review while supporting scientific platform development, team expansion, and preparations for commercial launch.
Loyal’s patents reflect metabolic, endocrine, and formulation strategies for canine longevity
Loyal’s patent portfolio shows how the company is building a canine longevity drug franchise through three key areas: metabolic health in senior dogs, growth-hormone and IGF-1 biology in large breeds, and long-acting veterinary formulations. These patents support Loyal’s lead programs and demonstrate its approach to developing longevity treatments backed by measurable biomarkers, defined mechanisms, and practical delivery methods.
PPAR-gamma agonists for metabolic aging in senior dogs
The problem
Senior dogs can experience age-related metabolic changes, including reduced insulin sensitivity and shifts in lipid metabolism. These changes may affect body condition, inflammation, energy use, and long-term health.
For a longevity drug, the challenge is not only treating aging in general. The treatment must connect to measurable biological changes that veterinarians, researchers, and regulators can evaluate.
How the patent solves it
U.S. Patent No. 12,161,636 introduces methods for using PPAR-gamma agonists, including pioglitazone, to address aging-related metabolic dysfunction in mammals. PPAR-gamma is a protein involved in fat storage, insulin response, and inflammation. Pioglitazone is a known PPAR-gamma agonist used to improve insulin sensitivity.
The patent links treatment to measurable markers such as insulin response, fasting insulin, fatty acids, triglycerides, cholesterol, and adiponectin. Adiponectin is a hormone released by fat tissue that helps regulate insulin response and fat metabolism.
Why it matters
This patent supports the logic behind LOY-002, Loyal’s daily pill program for senior dogs targeting age-associated metabolic dysfunction. It helps frame senior-dog longevity as a metabolic intervention supported by biomarkers. The patent is also strategically important because pioglitazone is already known. Loyal’s IP position therefore depends less on the molecule alone and more on how the drug class is applied to aging-related canine metabolism, dosing, formulation, and measurable outcomes.
The patent, titled “Method of increasing lifespan in mammals,” was filed on March 29, 2024, and granted on December 10, 2024. The listed inventors are Celine-Lea Halioua-Haubold, Michael LaCroix-Fralish, Matt Peloquin, Dina Juarez-Salinas, and Karen Greenwood. Legal representation is publicly associated with Wilson Sonsini Goodrich & Rosati.
Somatostatin analogs for GH/IGF-1 modulation in large dogs
The problem
Large and giant-breed dogs often have shorter lifespans than smaller dogs. Loyal’s large-dog strategy is tied to growth hormone and insulin-like growth factor 1, or IGF-1, which are involved in growth, metabolism, and body-size-related aging patterns.
The challenge is to connect that biology to a treatment approach that can be measured in companion animals.
How the patent solves it
WO2026006394A1 introduces somatostatin analog compositions and methods for companion animals. Somatostatin is a hormone that regulates other hormones. Somatostatin analogs are drugs designed to act like somatostatin and can reduce growth hormone and/or IGF-1 activity.
The filing links this treatment approach to biomarkers such as IGF-1, growth hormone, glucose, insulin, insulin sensitivity, and fatty acid concentrations. It also connects the approach to age-associated disease, frailty, insulin resistance, and health-related quality of life. The IGF-1 data supports the biological bridge between the proposed treatment and Loyal’s large-dog aging theory.
Why it matters
This patent gives Loyal’s large-dog programs a defined biological framework. It does not simply claim longer life in large dogs. It connects dog size, GH/IGF-1 signaling, treatment, biomarkers, and functional health outcomes.
That makes the filing relevant to LOY-001, Loyal’s veterinarian-administered long-acting product, and LOY-003, its daily pill program for large and giant dogs.
The patent application, titled “Somatostatin analogs and compositions and uses thereof,” was filed on June 25, 2025, and published on January 2, 2026. The listed inventors are Celine-Lea Halioua-Haubold, Michael LaCroix-Fralish, Dina Juarez-Salinas, Matthew Peloquin, Karen Greenwood, Laura Vasquez-Bolanos, and Ariel Howard Earle Cohen. Legal representation is publicly associated with Wilson Sonsini Goodrich & Rosati.
Extended-release octreotide formulations for long-acting veterinary dosing
The problem
A canine longevity treatment may need to be used for months or years. Daily dosing can be difficult for some owners and dogs, especially if the drug is intended for broad companion-animal use. For veterinary practice, a long-acting product may offer more consistent dosing and allow treatment to remain connected to regular veterinary monitoring.
How the patent solves it
WO2024206475A1 introduces extended-release octreotide dosage forms. Octreotide is a somatostatin analog, which links the formulation to Loyal’s GH/IGF-1 strategy for large and giant dogs.
The formulation uses biodegradable microspheres, which are tiny particles that can hold a drug and release it gradually. Instead of focusing only on the active ingredient, the patent centers on controlled release, dosing interval, and practical administration. The release-profile data supports the patent’s focus on sustained drug delivery, which is central to a veterinarian-administered long-acting product.
Why it matters
This patent protects the delivery layer of Loyal’s large-dog strategy. A competitor may target similar GH/IGF-1 biology, but would still need a viable formulation, release profile, dosing interval, and veterinary administration model.
That makes the filing relevant to LOY-001, which Loyal describes as a veterinarian-administered long-acting product for large and giant dogs.
The patent application, titled “Pharmaceutical formulations for longevity in mammals,” was filed on March 27, 2024, and published on October 3, 2024. The listed inventors are Ariel Howard Earle Cohen, Laura Vasquez-Bolanos, Celine-Lea Halioua-Haubold, Michael LaCroix-Fralish, Dina Juarez-Salinas, Karen Greenwood, Aiva Simaite, Duong Nguyen, Ivan Terzic, and Rob Steendam. Legal representation is publicly associated with Wilson Sonsini Goodrich & Rosati.
Loyal: Patenting Activity
As of writing, Loyal’s reviewed global patent portfolio includes 26 patents and patent applications grouped into five main patent families.
Some records identify the assignee as Cellular Longevity Inc., while others identify Loyal Animal Health Inc. Founder and CEO Celine Halioua declared a corporate name change from Cellular Longevity Inc. to Loyal Animal Health Inc., so the company’s regulatory documents are clearly tied to Loyal. For this article, both names are treated as part of the same Loyal company lineage.
| Patent Family | Title | Priority Date | First Publication Date |
| WO2022115739A1 | LNP and liposome compositions for longevity in mammals and methods of using the same | 2020-11-30 | 2022-06-02 |
| US12161636B2 | Method of increasing lifespan in mammals | 2023-03-27 | 2024-07-10 |
| WO2024206475A1 | Pharmaceutical formulations for longevity in mammals | 2023-03-27 | 2024-10-03 |
| WO2024263787A1 | Methods for measuring metabolic dysfunction or risk or presence of an age-associated disease | 2023-06-23 | 2024-12-26 |
| WO2026006394A1 | Somatostatin analogs and compositions and uses thereof | 2024-06-26 | 2026-01-02 |
The portfolio shows a progression from broad formulation work to more defined canine longevity programs. The earliest family, covering LNP and liposome compositions, points to drug-delivery research. Later filings move closer to Loyal’s current product direction in senior-dog metabolic aging and large-dog lifespan biology.
The “Method of increasing lifespan in mammals” family supports the senior-dog strategy, including metabolic aging and pioglitazone-related treatment. The octreotide formulation and somatostatin analog families support Loyal’s large-dog programs, with filings focused on long-acting dosing and GH/IGF-1 biology.
The metabolic dysfunction measurement family adds a biomarker layer to the portfolio. This is important because longevity drugs need measurable biological signals, not only broad claims about healthy aging. Together, the five families show a portfolio built around drug delivery, target biology, companion-animal use, and treatment measurement.
Expert Commentary: What Loyal’s innovation means for the future of longevity patents
According to Julie Carlisle, Partner and European Patent Attorney at Mewburn Ellis, Loyal is part of a broader trend towards treating aging as a modifiable biological process rather than simply managing the diseases that emerge later in life. She notes that if companies can demonstrate that interventions targeting fundamental aging mechanisms improve both lifespan and healthspan in dogs, “that will inevitably be watched closely by those working in human longevity research.”
Companion animals share many aspects of human environments and develop many of the same age-related conditions, making them particularly interesting from a translational research perspective. While the scientific, regulatory, and commercial pathways differ between veterinary and human medicine, companion animals can provide valuable real-world insights into how age-related decline can be measured and addressed.
Carlisle also points to the growing commercial opportunity for longevity therapeutics in companion animals. If these drugs become widely available, pet owners are increasingly focused on extending not just lifespan but also quality of life, while veterinary medicine continues to become more sophisticated in response.
More generally, Carlisle expects the pharmaceutical industry to continue investing in therapies that target the underlying biology of aging. She explains that the challenge, in both animal and human health, is generating robust evidence that a treatment is doing more than affecting a single disease endpoint. Companies are increasingly looking at biomarkers, metabolic pathways, and other measures of biological aging, and intellectual property is playing a key role in protecting those discoveries.
Building patent protection for longevity therapies
From a patent perspective, Carlisle explains that longevity therapeutics present some interesting challenges. Many programmes are built around known biological pathways, known compounds, or established mechanisms, which means innovators need to demonstrate a genuine technical contribution and carefully define what is new. Protection may therefore extend beyond the active ingredient itself to include specific dosing regimens, formulations, biomarkers, patient populations, methods of identifying suitable subjects, and associated diagnostic approaches. As technologies begin to overlap between veterinary and human applications, companies will also need to think carefully about global filing strategies and freedom-to-operate considerations across both sectors.
Looking ahead, Carlisle expects the patent landscape for longevity-related technologies to become increasingly competitive. “We are likely to see a greater volume of filings directed not only to therapies, but also to biomarkers, companion diagnostics, AI-driven assessment tools and personalised approaches to age-related interventions.” In such an environment, innovators will need to build layered patent portfolios that protect both platform technologies and individual commercial products. Early consideration of patent strategy, ideally supported by strong experimental data, will be critical to securing meaningful protection in what is becoming a highly active area of innovation.
Carlisle adds that, from Mewburn Ellis’ perspective, longevity therapeutics sit at the intersection of several areas the firm has been following closely within animal health. As its work on animal health and ‘One Health’ has highlighted, innovations developed for veterinary use can have implications far beyond the veterinary sector, creating a valuable exchange of knowledge between animal and human medicine.
Loyal: Top Technology Areas
Loyal Animal Health’s patent activity is concentrated in A61K and A61P, which cover medicinal preparations and therapeutic applications, highlighting the company’s focus on drug formulations and prescription-based strategies aimed at extending canine healthspan and longevity. The portfolio also includes filings under A23K, a classification related to animal feeding and nutritional formulations, reflecting efforts to adapt treatments and delivery approaches specifically for companion animals.
In addition, patents classified under G01N, which covers the investigation and analysis of materials through chemical or physical testing, demonstrate the importance of biomarkers and biological measurements in the company’s research. Together, these areas indicate a development strategy that combines therapeutic innovation, animal-specific formulation expertise, and scientific validation to support healthier aging in dogs.
Loyal: Top Legal Representatives
Loyal Animal Health’s patent portfolio has been supported by a combination of leading intellectual property law firms and individual patent attorneys. Wilson Sonsini Goodrich & Rosati appears as the primary legal representative, while additional patent work has been handled by Gowling WLG, FB Rice, Reinhold Cohn & Partners, Mewburn Ellis, and Lee International IP & Law Group.
The company has also worked with patent attorney Lorena Rodriguez Chavez from ClarkeModet, indicating a diverse legal network supporting its global intellectual property and patent prosecution activities.
OUR FEATURED GUEST
JULIE CARLISLE
Partner and European Patent Attorney, Mewburn Ellis
Julie is a partner and European patent attorney specialising in pharmaceutical patent work, with a particular focus on complex and contentious matters before the EPO.
Her practice centres on protecting and defending commercially important pharmaceutical inventions, including late stage clinical candidates and approved drug products.